FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Stock Option (Right to	\$6.42	11/02/2020		Code		V	(A)	3,000		8)	08/13/2029	Commo Stock	3,000			238,6	16 D	
					Code	\ \ V	(<u>A)</u>	(D)	Date	isahla	Expiration Date	Title	Amour or Number of	er				
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Do Execu	3A. Deemed Execution Date,			5. Number		6. Dat	tions	cisable and	DIE SECURITIE 7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Do Se (Ir	. Price of lerivative lecurity nstr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Owners Form: Direct (or Indir (I) (Instr	Beneficial Ownership ect (Instr. 4)
Common Stock														16,579		I See footnote		
Common Stock													16,579		579	I	See footnote ⁽⁶⁾	
Common Stock													104	,449	I	See footnote ⁽⁵⁾		
Common Stock													104	,449	I	See footnote ⁽⁴⁾		
Common	ommon Stock												23,	090	I	See footnote ⁽³⁾		
	mmon Stock 11/02/202							S ⁽¹⁾		83	D	\$31.87			,923	D		
	ommon Stock 11/02/202 ommon Stock 11/02/202							M S ⁽¹⁾		3,000	A D		\$6.42 31.1329 ⁽²⁾		,923	D D		
						(Month/Day/Yea		rear)	8) Code	v	Amount	(A) or (D)	File		Owned Followin Reported Transaction(s) (Instr. 3 and 4)		(I) (Instr. 4)	Ownership (Instr. 4)
1. Title of Security (Instr. 3)			2. Transactic Date (Month/Day/	n	2A. Deemed Execution Dear) if any		ite,	3. Transaction		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amo Securi Benefi		ount of ties cially	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial	
(City)	(S		(Zip)		<u> </u>													
(Street) CAMBRIDGE MA 02142				- 4.										Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET				11.	3. Date of Earliest Transaction (Month/Day/Year) 11/02/2020								See Remarks					
1. Name and Address of Reporting Person Epstein David M.						2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [BDTX]								Check X	all applic	cable) or	ting Person(s) to Issuer 10% Owner Other (specify	

- 1. Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$30.74 to \$31.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 4. Shares held by David M. Epstein 2019 Trust For Elle. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Elle and may be deemed to beneficially own these securities.
- 5. Shares held by David M. Epstein 2019 Trust For Zoe. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Zoe and may be deemed to beneficially own these securities.
- 6. Shares held by David M. Epstein 2019 Trust For Robert. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Robert and may be deemed to beneficially own these securities.
- 7. Shares held by David M. Epstein 2019 Trust For Shelley. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Shelley and may be deemed to beneficially own these securities.
- 8. 25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Officer Title: President and Chief Executive Officer

/s/ Brent Hatzis-Schoch, as Attorney-in-Fact

11/03/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.